• E Rowinsky, L Smith, G Rodriguez, L White, R Drengler, D Von Hoff, N Peacock, C Aylesworth, H Burris, P Ravdin, and R Bellet.
• Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, USA.
• Oncology Ny. 1997 Jun 1; 11 (6 Suppl 6): 33-5.

AbstractThe relatively recent introduction of a new class of chemotherapeutic agents--the taxoids--has raised hope of improved survival for patients with advanced or metastatic cancer. Following encouraging preclinical results of taxoid combinations, this phase I, nonrandomized trial was designed to evaluate a 1-hour intravenous infusion of docetaxel (Taxotere) on day 1 combined with fluorouracil (5-FU) as a daily intravenous bolus for 5 consecutive days. To date, 27 patients with advanced solid neoplasms have received 86 courses of docetaxel/5-FU at the following dose levels: 25/100, 35/150, 50/200, 60/200, and 60/300 mg/m2. Preliminary results showed no unexpected toxicities, and the principal toxicity was neutropenia of short duration. A treatment regimen of 60 mg/m2 docetaxel on day 1 and 300 mg/m2 of 5-FU given for 5 days, with a single course length of 28 days, is projected as the maximum tolerated dose.

20 keywords...

hide…